Monday, March 09, 2009

Rx: Take TRA if you are running out of Singulair

Pharmaceutical goliath, Merck, faced with an upcoming patent expiration on its big seller Singulair (~18% of company sales) is positioning to buy rival Schering-Plough, whose clot-buster TRA is expected to do quite well in the marketplace. Merck already cut over 7,000 jobs last fall.

Update: the deal is done, for $41.1 billion. The New York Times reports.

No comments: